VBCRC Laboratory, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; University of Melbourne, Parkville, VIC 3050, Australia.
VBCRC Laboratory, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; University of Melbourne, Parkville, VIC 3050, Australia; Department of Medical Oncology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia.
Cell Stem Cell. 2012 Jun 14;10(6):717-728. doi: 10.1016/j.stem.2012.05.007.
The cancer stem cell (CSC) model has been established as a cellular mechanism that contributes to phenotypic and functional heterogeneity in diverse cancer types. Recent observations, however, have highlighted many complexities and challenges: the CSC phenotype can vary substantially between patients, tumors may harbor multiple phenotypically or genetically distinct CSCs, metastatic CSCs can evolve from primary CSCs, and tumor cells may undergo reversible phenotypic changes. Although the CSC concept will have clinical relevance in specific cases, accumulating evidence suggests that it will be imperative to target all CSC subsets within the tumor to prevent relapse.
癌症干细胞 (CSC) 模型已被确立为一种细胞机制，有助于不同癌症类型中的表型和功能异质性。然而，最近的观察结果强调了许多复杂性和挑战：CSC 表型在患者之间可能有很大差异，肿瘤可能含有多个表型或遗传上不同的 CSCs，转移性 CSCs 可以从原发性 CSCs 进化而来，肿瘤细胞可能经历可逆的表型变化。尽管 CSC 概念在某些情况下具有临床相关性，但越来越多的证据表明，必须针对肿瘤内的所有 CSC 亚群进行靶向治疗，以防止复发。
